Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355134 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis
A Phase 3 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,083
- Enrollment target
NCT00355134 is a Phase 3 study that has completed, run by Novartis. The registered enrollment target is 1,083 participants.
The verdict
NCT00355134, a Phase 3 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,083 participants
- Enrollment target
Study Summary
This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
Interventions
- DRUG Placebo
- DRUG Fingolimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,083 participants |
| Start Date | 2006-06 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355134
The ClinicalTrials.gov registry entry for NCT00355134 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,083 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00355134 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355134 about?
NCT00355134 is a clinical study titled "Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis". This study assessed the safety, tolerability and efficacy of two doses of oral fingolimod compared to placebo on efficacy parameters in patients with relapsing-remitting multiple sclerosis (RRMS).
What is the current status of trial NCT00355134?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,083 participants. The study started on 2006-06. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00355134?
The interventions under investigation include: Placebo (DRUG), Fingolimod (DRUG).
Who is sponsoring clinical trial NCT00355134?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.